Global "Gastroesophageal
Reflux Disease (GERD) therapeutics Market" 2025 Industry research report covers the industry overview with
Marketplace Size, Share, Development, futuristic cost, earnings, demand and
distribution data. Its vast repository offers an analytical summary of the
marketplace that can help to the new and existing player to take a significant
decision.
In this report, we
thoroughly examine and analyse the Global market for Gastroesophageal Reflux
Disease (GERD) therapeutics so that market participants can improve their
business strategy and ensure long-term success. This report provides players
with useful information and suggests result-based ideas to give them a
competitive advantage in the global Gastroesophageal Reflux Disease (GERD)
therapeutics industry. It will show how other players compete in the global Gastroesophageal
Reflux Disease (GERD) therapeutics Market and explain the strategies you use to
differentiate yourself from other participants.
Download Free Sample
Report Now @ https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample
Industry Insights
The global Gastroesophageal
Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion
in 2016 and by is estimated to be USD 4.34 billion by 2025, it is anticipated
to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of
patented blockbuster drugs, which are indicated for the management of disorders
of acid reflux is major restraining factors for this market.
With strong clinical
pipelines and patent litigations, the market continues to experience
significant changes. Proton pump inhibitors (PPI) and antagonists of histamine
H2 receptor have the importance in current scenario of the market.
Upon loss of patent
protection of formerly leading branded drugs, generic molecules with low-price
can ingest the sales of the branded ones up to 90%. Rising number of companies
being exposed to price scrutiny associated with shift in the focus of
government on the promotion of consumer convenience will stimulate further
reduction of drug prices. Although market turnover is affected by the
expiration of major patents and the demand of drugs used to reduce acid, due to
the increasing prevalence of heartburn, is anticipated to increase in the
upcoming years.
The devices of GERD serves
as a substitute for management of heartburn, because of low rate of success and
failure in clinical trials. Hence, very limited acceptance of devices of GERD
management contribute for the rising demand of drugs having acid neutralizing
property, as the major therapy approach.
Nevertheless, the advent of
devices which are minimally invasive to address anatomical defects are gaining
popularity coupled with supportive evidence from clinical data for performing
various procedures including trans oral fundoplication, which helps in
preventing reflux of non-acid and acid contents. The adoption of these devices
have been further reinforced in the U.S. in 2016 with the advent of a CPT code
(43210) which helps in facilitating reimbursement process.
Regional Insights
In 2016, the largest region
was found to be North America in terms of share for GERD market. Every year,
GERD symptoms are experienced by more than 80 million people in the U.S., of
which, approximately 25 million patients suffer from acid reflux and heartburn
daily and approximately 60 million patients monthly.
Moreover, outpatient clinic
visits for GERD disorder in the U.S. has been increased in the past few years
because of the more prone geriatric population to develop acid reflux and
heartburn. On the contrary, the Asia Pacific is estimated to witness the
fastest growth rate. The increasing geriatric population and dietary and
lifestyle risk factors such as diet with high fat and obesity, is anticipated
to drive the growth. In developing countries, the inclination towards
self-medication is quickly increasing because of the affordability and
availability of OTC antacids as in China and India.
Competitive Insights
Competitive market, which
is generics-driven is creating a pressure on the prices of drug with decreased
retail sales, which will stimulate stationary growth in future. Companies
producing them range from high to medium on the basis of competitive rivalry.
Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson
and Takeda Pharmaceutical Co., Ltd.; are some of the top key players. In
addition, Daewoong Pharmaceutical Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; SFJ
Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are some emerging
companies.
Among others, RaQualia
Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing more on
development of new generic molecules, which involves novel and existing drug
mechanisms as a part of the strategy to enter into the competition. Many
generic players are also trying to focus on these spaces in an attempt to
capture a larger share by the new version to replace the patent expired drugs.
Know
More Insights @ https://newsonmarketblog.wordpress.com
No comments:
Post a Comment